News

Parkwalk

Parkwalk

Ascendant report highlights Parkwalk as one of the busiest UK venture investors in 2013 – read more here

Xeros

FT: UK firm launches domestic near-waterless washing machine
Xeros, which claims its near waterless washing machine is the first genuine innovation in laundry for 60 years, is close to launching a domestic model in the US.
The Rotherham-based company intends to raise fresh capital to start production after selling commercial versions to a string of customers in the US and UK, with a public offering one option being looked at by Jefferies, the investment bank.
s

……..read more at the FT

Cambridge Enterprise

A huge thank you to all the team at Cambridge Enterprise for an excellent University of Cambridge Enterprise Fund investor evening yesterday at Emmanuel College.
Investee companies presenting included:
Aqdot (highlighted in the FT yesterday)
Cambridge CMOS Sensors
DefiniGEN
Inotec AMD
Sphere Fluidics
as well as three very exciting potential investee companies for the University of Cambridge Enterprise Fund II

Omega Diagnostics

CD4 Update – Successful completion of Technology Transfer – Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the successful completion of its CD4 technology transfer project with first in-field evaluations to start next month.

Further to the announcement made in December 2013 regarding the first reference batch, the Company announces that it has successfully completed a three batch-validation of its manufacturing protocol. The results from tests on patient samples with the second and third batches have demonstrated that Visitect(R) CD4 meets the design parameters of clinical sensitivity, specificity, accuracy and reproducibility.

This is a major milestone towards full commercialisation of the Visitect(R) CD4 test and accordingly, the product is now available for full in-country field evaluations. The first evaluations are expected to commence next month in Kenya and Mozambique. Separate claim-support studies are planned to CE-Mark the test which will take place over the next few months.

The devices for the second and third batches were assembled using the Company’s Alva-based manufacturing facility which was built last year, and this completes the equipment validation process required under ISO 13485. Accordingly, the Company now has a fully validated production facility, currently capable of manufacturing over seven million devices per annum.

Commenting on the completion of technology transfer, Andrew Shepherd, CEO of Omega said: “We are delighted to have successfully completed the milestone of technology transfer for this innovative product. This now unlocks the full potential of Visitect(R) CD4 which is eagerly awaited by the market.”

Arkivum

University of London Computer Centre (ULCC) and Arkivum Ltd. announce partnership – The partnership enables ULCC’s Academic & Research Technologies team to offer an integrated, long term digital preservation solution to the academic, heritage and special collections sector – read more

Aqdot

Highlighted in the FT: Oxbridge: Aqdot Selected UK Tech stocks causing a stir

Founded: 2012
Founders: Roger Coulston and Jing Zhang
Employees: 10
What they do: Make capsules for storing and releasing chemicals
Who they want to be:
The next Bayer
Total funding: £1m

When you swallow a pill you probably care more about the ingredients that are inside than the casing that holds them in. But such “encapsulation” will be a $40bn market in 2015, say the founders of Aqdot – a company founded by researchers at Cambridge university.…….. read more

Xeros

The Times: Beads put new spin on global industry (Xeros Feb 10 2014) – read more

Clean Air Power

Concept Development Agreement: Clean Air Power (AIM: CAP), the developer and global leader in Dual-Fuel engine management software for heavy duty vehicles, today announces that it has entered into a funded concept development agreement with a global truck manufacturer to develop a Dual-Fuel engine for a South East Asian market. This is the first program to be awarded through the cooperation agreement with Ricardo, Inc, signed in September 2013.

The purpose of the development program is to utilise Clean Air Power’s Dual-Fuel™ combustion technology to deliver an advanced dual-fuel engine that not only achieves its emissions objective but also reduces the extent of emissions after-treatment required by the base diesel engine.

Subject to a successful concept phase, expected to last 6 months, the agreement will then enter a second stage to bring the advanced dual-fuel engine to start of production.

Commenting on the agreement, John Pettitt, CEO of Clean Air Power, said:

“It is a pleasure to be announcing a concept study so quickly after entering the cooperation agreement with Ricardo. This is a very exciting but challenging program which highlights the interest in our technology in major world markets including Asia.”

Horizon Discovery

Appointment of Chairman – Horizon Discovery has appointed Dr. Ian Gilham as Chairman of its Board of Directors.

Dr. Gilham’s healthcare industry career spans thirty years encompassing all aspects of successful company growth and development. He was Chief Executive Officer of Axis-Shield plc, prior to its sale to Alere and he has also held top management positions at GSK, Abbott Laboratories, Celltech and Amersham, gaining wide expertise in the fields of pharmaceuticals and clinical diagnostics.

Ian Gilham

Xeros

Smithsonian Magazine – This Washing Machine Could Be the Next Game-Changing Appliance.

An innovative system that uses stain-sucking plastic beads translates to big savings

When it comes to revolutionary inventions of the 20th century, electric washing machines are right up there with automobiles and personal computers. With the press of a button, a load of laundry that had once taken in excess of four hours to clean was reduced to a 40-minute automated process. Some economists have even credited the time-saving appliance with precipitating the rise of women in the workforce during the 1950s, as homemakers were suddenly freed up to take up other pursuits….. read more
xeros_800x600

Friday Thoughts

Stock market corrections…. With the S&P now down around 8% from last months all time highs (at time of writing), and other western stock markets making similar moves, we are currently somewhere between what we would call a ‘dip’ and a ‘correction’.

(See below table)

For what it’s worth, I have no idea whether this recent dip is the start of a new bear market or whether stocks are going to blast off to the moon again.
I do know though, that nobody else knows either.
Amongst all the inevitable hysterics of financial commentary, it is best to try not to play for either team – bulls or bears.

Capture

So, what to do during corrections?
I’d recommend keeping a list of high quality stocks you’ve been kicking yourself for missing out on and clear the decks of anything you currently own which you don’t truly love.
For those with time horizons of more than 5 years (most), the best thing to do is grit ones teeth and do very little.
If a correction of 15-20% is unbearbale, then you’ve either got too much money invested in stocks, or you’re a bit of a fairy.
Make the adjustment you can live with.

Nobody knows if the correction will become a bear market (or even worse, a crash), but this is always possible.
But, most corrections (as shown throughout history) do not become crashes, and every single one of them turned out to be great buying opportunities in the fullness of time.
Stay cool….

Emerging markets…. Time to have a dabble…?

I am increasingly thinking that this continued EM sell-off is offering up an opportunity for medium/long term investors.
It has been extremely difficult to find some distressed ‘value’ in equity markets of late, and this could be just that.
However, this has also been a good reminder of a few things to consider when investing in this asset class.
Firstly, there is going to be volatility in these markets, and this must be expected. It is unlikely to change for some time.
Secondly, it is important to note that despite often being mentioned in the same group, not all ’emerging markets’ are created equal.
Issues facing countries like Turkey and South Africa are not the same as ones facing the likes of China and South Korea. Despite the dour headlines, some markets are actually more reilient than they appear. For example, both China and South Korea are running current account surpluses and have large FX reserves, and so Fed tapering is likely to impact emerging markets differently.
Countries dependant on foreign funding, such as Turkey and S.A are likely to struggle in contrast to China and Korea. The chart below showing Y/Y currency changes outlines the difference.

Capture

Thirdly, it is also a truth that emerging markets offer deep value.
Given that they are growing faster than those in the developed world, they still look cheap by most metrics. Currently, EM equities are trading at about a 40% discount to developed country stocks, representing the largest discount since the financial crisis.

It shows us that it is impossible to time markets.
That said, some EM markets will soon start to look very attractive on a long term view, although not all equally attractive, and it is important to take a more discerning approach to the EM asset class.
The bottom line, if you want some exposure to the economic growth of the emerging markets, and are happy to allocate over the medium/long term and ride out the storm there is likely to be some selectively found value – now, if not soon.

Other bits of interest….

Twitter falls on weak user growth…..

Sochi shambles…

Tempo…

 

 

 

 

 

 

 

Mode DX

Parkwalk closes Opportunities Fund and syndicate investment into Mode Diagnostics:

Mode Diagnostics Ltd – Receives approval to commence sales of its digital home-use bowel-screening test; successfully completes significant financing round

06 Feb 2014

MODE Diagnostics Limited (“MODE” or “the Company”) today announces that it has received a European CE mark for its first product, measure Bowel Health, a user-friendly digital bowel cancer screening test for the home use market.

MODE also announces that it has successfully completed a significant funding round led by new investor Longwall Venture Partners. The financing was also strongly supported by existing investors including IP Group plc, Parkwalk Advisors and Scottish Enterprise’s Scottish Investment Bank. Funds raised will be used to support the launch of measure Bowel Health into key European markets as well as on developing a product pipeline centred-around MODE’s proprietary digital screening platform – measure.

Dr. Paul Heaney, CEO of MODE, added “The Company has made major technical and regulatory strides in a short period and we are now preparing for product launch into a series of markets. We are delighted to welcome new and returning investors at this exciting phase in the company’s growth”. Heaney continued “Bowel Cancer is the third highest mortality rate cancer in UK and around the Globe but early detection is proven to dramatically improve these survival rates. Our mission is to make well designed, hygienic and easy to use screening tests that will encourage individuals to screen regularly and catch problems early”.

measure BOWEL HEALTH represents an evolution in bowel cancer screening (faecal occult blood detection) offering significant technical and user-orientated improvements over the current testing methods. The CE Certification was received following review by an external notified body and enables MODE to sell measure into the ‘over the counter’ home health screening market. The approval follows MODE’s earlier achievement last year of ISO 9001 and ISO 13485 quality management systems.

MODE’s proprietary platform – measure – is a flexible, low-cost and hygienic platform that can easily be configured to create a series of health tests for both the Physicians Office and Consumer self-testing.

Michael Penington, Partner at Longwall Ventures, commented “MODE as a company offers entry into exciting new healthcare markets with modern and appealing user friendly devices – health screening for the 21st Century. These devices help promote the concept of early detection that can lead to early intervention and effective medical treatment outcomes – this is key to the new paradigm being pursued by pioneering Healthcare providers and empowers the individual”.

Kerry Sharp, Head of the Scottish Investment Bank, commented, “SIB, through its Scottish Venture Fund, is delighted to further support this ambitious Scottish life sciences company. MODE has shown a commitment to innovation and the development of new products that enhance healthcare provision, and we are pleased to be able to build on previous Scottish Enterprise support from SMART: SCOTLAND to help them accelerate their growth plans”.

– END –

Contact
MODE Diagnostics Ltd
CEO: Dr Paul J Heaney
Tel: + 44 141 330 8675
Email: Paul.Heaney@ModeHealth.com

About MODE: MODE is an innovative product development company rapidly building a pipeline of user friendly and medically informative health screening products specifically designed for the Physicians office and consumer self-testing.

About Longwall Venture Partners: Longwall Venture Partners is an Oxford based, venture capital fund management company. Longwall specialises in managing early stage investments in science, engineering and technology start-ups. It manages the £30m Oxford Technology ECF and the £40m Longwall Ventures ECF.

About IP Group: IP Group is a leading UK intellectual property (“IP”) commercialisation company, developing technology innovations primarily from its research intensive partner universities. The Group offers far more than traditional venture capital, providing its companies with access to business building expertise, networks, recruitment and business support.

About Parkwalk Advisors: Parkwalk invests in innovative UK growth companies across various stages of their development. Parkwalk Funds seek capital appreciation, with the added advantages to investors of the tax reliefs offered under the Enterprise Investment Scheme (EIS) and Business Investment Relief (BIR).

About Scottish Investment Bank: The Scottish Investment Bank is the investment arm of Scottish Enterprise, operating Scotland-wide in partnership with Highlands and Islands Enterprise. It manages a suite of funds including the Scottish Co-investment Fund and the Scottish Venture Fund, which are partly funded by the European Regional Development Fund (ERDF); the Scottish Seed Fund, the Scottish Plastics Loan Fund and the Renewable Energy Investment Fund. SIB is also the cornerstone investor in the privately-managed Scottish Loan Fund and an investor in the Rock Spring Ventures Life Sciences Fund. These support Scotland’s SME funding market to ensure businesses with growth and export potential have adequate access to capital. SIB also provides a team of financial readiness specialists to help companies prepare for new investment and more easily access finance.

Xeros

Daily Express: Green washing machine invention puts rivals in a spin

THE British maker of a revolutionary green washing machine using nylon beads largely to replace water and detergent has now set its sights on the leather and textile processing industries……

Tracsis

Positive Interim Trading Update – Tracsis plc, a leading provider of software and technology led products and services for the transportation industry, is pleased to provide an update on trading ahead of the release of its interim results for the six months to 31 January 2014.

Trading has been strong in the first half of the financial year with revenues expected to be in excess of £9m (2013: £4.7m). Both revenue and profit are in line with expectations. The Group’s balance sheet remains strong with cash balances in excess of £7m and the Group remains debt free.

Sky High, which was acquired in April 2013, made a significant contribution to the overall Group.  The integration of this business is progressing well and is expected to be complete by financial year end.

In January, the Group announced a significant order for its condition monitoring technology with a major UK client.  Delivery of this is under way and will be completed during the current financial year.  In addition, the Group’s North American pilot for this technology, announced in November 2013, is progressing to plan.

The Software and Consultancy business has been working extensively on rail re-franchising bid work following the revised timetable issued by the DfT and there is good visibility on workload over the coming months.  The Group also converted 100% of its software renewals for H1.

The Board intends to recommend an interim dividend in due course as part of its progressive policy.

 

For more information please contact:

John McArthur/Max Cawthra, Tracsis plc Tel: 0845 125 9162
Katy Mitchell, WH Ireland Limited Tel: 0161 832 2174
Rebecca Sanders Hewett/Jenny Bahr, Redleaf Polhill Tel: 0207 382 4730

Tracsis@redleafpr.com

 

Notes to editors:

§ The Group specialises in solving a variety of data capture, reporting and resource optimisation problems along with the provision of a range of associated professional services.

§ Tracsis’ products and services are used to increase efficiency, reduce cost and improve the operational performance and decision making capabilities for clients and customers.

§ The Company offers the following services:

–  Software and technology led consulting: Industry strength resource optimisation software that covers a variety of asset classes working alongside consulting and related professional services across the operational and strategic planning horizon.

–  Remote Condition Monitoring: Technology and reporting for critical infrastructure assets in real time, to identify problems and aid with preventative maintenance.

–  Data Capture: Collation and analytical services within traffic and pedestrian rich environments.

§ Tracsis has a blue chip client base which includes the majority of UK transport operators such as Arriva, First, Stagecoach, Go-Ahead, National Express and Virgin.  The business also works extensively with Network Rail, the Department of Transport, multiple local authorities, and a variety of large engineering/infrastructure companies.

§ Tracsis has offices in the UK and Australia which service projects in Europe and Australasia.

§ The business drives growth both organically and through acquisition and has made five acquisitions since 2008.

§ Tracsis listed on AIM in 2007 under ticker TRCS.

§ For more information visit http://www.tracsis.com

Friday Thoughts

Emerging Markets: What’s going on….?? Emerging market currencies have fallen to their lowest level since 2009.

Argentina has hit the headlines, but Turkey, South Africa and Russia have also been hit hard. There has been violence on the streets of Kiew and Bangkok.
The scare has quickly dragged down the S&P, followed by the Asian stock markets.
How worried should we be?

Firstly, this is nothing new and certainly not out of the blue. It has been brewing for a while.
Emerging market countries have been walking on the wild side for some time, certainly since May, when the Fed made it’s first attempt to start winding down its bond purchases.
Since then, investors have been shifting out of EM, when long term interest rates began rising in the US.
This prospect of an end to ‘free money’ has caused funds to be pulled from emerging markets which have been benefiting from a decade of easy inflows, and so currencies and stock markets tanked. This seemed to have stabilised over recent months, but crises tend to come in fits and starts rather than one big bang.

A couple of things have not changed, and some argue have even got worse.
Firstly, there is still no clear indication from the rich world’s central banks on how they will tame the beast they have created through loose monetary policy. Secondly, the emerging world’s recovery in exports looks
decidedly average. The hope was that as the rich world recovered faster, it would demand more goods from emerging economies and become less dependent on foreign capital inflows. But stats are mixed as China’s exports have grown slower than expected, and Brazil and Turkey’s current account deficits have widened.
China is the one economy that serves as a proxy for western appetite for exports, and a source of demand for commodities. At each sign of a China slow down, investors run from emerging economies.

From looking at the worse hit countries, even as their currencies are coming under pressure, this latest panic seems to be as much about politics as anything else.
There are too many fires burning.
South Africa is facing a wave of unrest, Turkey’s currency has collapsed due to a corruption scandal, Ukraine is being racked by huge protests, and Venezuala is a political wreck. Perhaps more countries facing political instability or social unrest may cause a further spread from these troubled spots, and this is not impossible with India and Indonesia facing elections this year.
A second trigger could be the state of the financial system, and the banks in the emerging economies. All emerging countries have shared in the huge credit boom and loans have been growing by double-digit rates for many years.
Have a look at the share price of Standard Chartered, a bank largely exposed to the emerging world. It has collapsed.

So, two things to look out for signs that the recent wobble may turn into something more sinister.
First , the streets, and for more social unrest.
Second, the banks and rotten loans.
For now, these events are only going to drive more people towards safer, more politically stable economies, currencies and markets.
But for those with a long term view, and the stomach to ride out some volatility, this may eventually provide an opportunity.
The long term
What should we be looking for….?

Talking of the longer term, what exactly does that mean?
Most talk of long term investing as up to a 10 year horizon, a time-frame in which a hell of a lot can happen.
For that reason, a long term investment is going to have to meet several criteria.

1. unlikely to be disrupted by technology
2. meet a need somewhere towards the bottom of Maslow’s pyramid
3. produces a yield
4. expectation of capital gain

With this in mind, one of my favoured 5-10 year investments would be in agriculture/farmland.
For the following, fairly simple reasons.

1. the customer base is growing (population)
2. supply is limited (‘buy land, they’re not making it any more’ etc)
3. the customers have little choice about buying the product (food)
4. it produces a yield

Concerns about the ability to feed a population of 6 billion people, expected to rise to 9 billion by 2050, are of course well documented. According to the UN, food production will have to increse by 70% to feed the world’s larger, more affluent and more urbanised population by 2050.
Efforts to control food prices and the means to produce it are being viewed as the ‘new oil’ of the 21st century.

So how can you invest in the agriculture industry?
Of course you could get your hands dirty, buy a farm and become a farmer.
Not so easy, and maybe best left to the experts….
There are several funds which buy global agriculture land/assets. Look for those investing in political stable countries, and with growing populations.

Alternatively, you can invest in companies which provide inputs and equipment – such as fertiliser, seed and machinery – to the agriculture sector.
Or provide financing for farmers.
Or as Jim Rogers says ”open a chain of restaurants in the Midwest or in the Australian outback, or open a Lamborghini dealership there because the the farmers will be driving the Lamborghinis and the stock brokers driving the tractors”.

……here are a few more popular ‘long term’ investment themes worth thinking about….

– Chinese Consumer Sector – ”long term no brainer” Jim O’Neill

– International Healthcare – the thought being once emerging middle classes have satisfied their demand for leather counches and flat screen TV’s their demand will refocus on healthcare, this combined with the increase in health threats from internal pollution, environmental threats and ageing populations. It could be the next ‘perfect storm’. Exposure can be gained by the Worldwide Healthcare Investment Trust (WWH LN).

– Energy intensive US manufacturing – any company likely to benefit from the shale gas revolution, and able to lever off the emerging market consumer
Parkwalk Update

At a different end of the investment spectrum, is what we do at Parkwalk.
We look for disruptive technologies which will transform markets.
Xeros, an investment in our Portfolio is a classic example of this, and the company has recently announced an upcoming IPO (expected to be at between 6 – 12 x our investment price 3 years ago).
See: www.youtube.com/watch?v=Hr0Vei-cmXE&feature=youtu.be

On a wider scale, we have seen further indication of an increase in the interest in the assets of UK University Technology spin-outs, with IP Group (the FTSE 250 listed specialist) buying Fusion IP (a smaller version) at 82p a share which values Fusion at £87.8m. This is around 2x gross assets.
IP Group’s share price itself is also currently trading at 2.1x NAV.
Such is the excitement and potential in this sector, investors are prepared to pay twice what these companies are ‘worth’ in the expectation of future returns.
Parkwalk co-invest in several IP Group deals, and with the additional tax reliefs offered via the EIS, investors in Parkwalk funds are investing at a 30% discount to NAV rather than a multiple.
This offers a huge opportunity for individual investors.
We expect to find many more Xeros’s in the future.

Other bits of interest….

Facebook – the first $1bn Ad quarter…..
Apple – iPhone sales miss….

 

Horizon Discovery

Horizon Discovery Signs Large-Scale License Agreement for its X-MAN Cell Lines in Japan

Agreement covers use of 250 of Horizon’s X-MAN genetically defined isogenic cell lines

Cambridge, UK, 30 January 2014: Horizon Discovery™ (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has entered into a large-scale licensing agreement with a Japanese medical university. The agreement covers a limited use label license for academic use of 250 of Horizon’s X-MAN™ genetically defined, isogenic cell lines, and demonstrates the global recognition of the company’s in vitro disease models.

Fund Managers Comments – January 2014

It has been a very interesting start to 2014, with Xeros, an investment in the UK Tech Fund I, recently announcing it is exploring the possibility of a float on the AIM market at potentially several times the level of our original investment.

We have seen further indication of the interest in investing in the assets of UK University Technology spin-outs, with IP Group buying Fusion IP at 82p a share (cash and IP Group shares) which values Fusion at £87.8m (Fusion closed at 63p). The last figures from Fusion on 31/7/13 valued their portfolio at £25m and cash in balance sheet of £21.7m. Therefore this is around 1.9x gross assets. IP already owned 20% of IP and has preferential rights to investing in Fusion companies.
At the same time IP Group is raising a further £75m to £100m at 165p a share against a net asset value of 77p a share reported at October 30th 2013, or 2.1x net assets.

Public Markets
The public market has, since September 2013, seen a rise in asset values in this space. From the IPOs of Kromek (listed at 51p now trading at 75p) and Applied Graphene Materials (listed at £1.55p now trading around £4.00) to the rise in share prices at the publically quoted fund managers, IP Group and Imperial innovations and now confirmed by the financial Institutions backing IP Group at these valuations in this transaction.

Our own experience is that this is having a knock-on effect in the private market and that there is more money chasing investment than before (leading in two recent cases to investors being scaled back in their demand in deals with which we are involved).
This may indicate the market is beginning to turn from being a straight buyers market with investors dominating the investment terms discussion with companies. In turn this could make it more difficult for newcomers to invest in this space.

Discount to NAV
With the additional tax reliefs offered under the EIS, investors in Parkwalk Funds are investing at a 30% discount to NAV rather than a multiple.

We have recently launched our Parkwalk UK Tech Fund V to investors (aiming to invest over the tax year 2014/15) some of whose investment will be in follow-on rounds from our existing portfolio of 27 companies, thereby allowing us to sidestep any difficulties others might have in finding suitable investments in 2014/15.

Recently Closed Investments
In the last three months Parkwalk have lead an investment into Arvia Technologies, lead a £5m round into Oxford spin-out YASA Motors and closed follow-on funding rounds into three other portfolio companies – please be in touch if you would like further details of these investments.

Portfolio Updates
We have also met with or spoken to the management of many of our portfolio companies over recent months, so if you would like an update, please be in touch.

OxfordPV

Kevin Arthur, CEO at Oxford Photovoltaics, discusses the company’s technology providing solar energy through windows. He speaks on Bloomberg Television’s “The Pulse.”

How to Turn Windows Into Solar Panels: Video

Tracsis

Tracsis  – wins undisclosed overseas order – Tracsis plc, a leading provider of software and technology led products and services for the transportation industry, is pleased to announce that it has received an order for an undisclosed six figure sum to supply its Remote Condition Monitoring equipment and associated software to a customer in Ireland.

As communicated at its preliminary results, the Group is focused on building its overseas presence and this order is further evidence of the Group’s progress in doing so.

At this point in time the Group’s forecasts for the current financial year remain unchanged.